The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

Share Price Information for CATCo (CAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.00
Bid: 13.00
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 22.00 (169.231%)
Open: 24.00
High: 24.00
Low: 24.00
Prev. Close: 24.00
CAT Live PriceLast checked at -
CATCo Reinsurance Opportunities is an Investment Trust

To provide investors with significant capital returns and long-term distributions by making investments linked to catastrophe reinsurance risks via a variety of insurance-based investments.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Compulsory Acqn of Shares

30 Nov 2022 07:00

RNS Number : 0009I
CATCo Reinsurance Opps Fund Ltd
30 November 2022
 

CATCo Reinsurance Opportunities Fund Limited (the "Company")

30 November 2022

Partial Compulsory Redemption of Shares

Following the redemption of 1,379,027 Ordinary Shares at a rate of $3.3355 per Ordinary Share and 754,052 C Shares at a rate of $17.5042 per C Share on 29 November 2022 (as previously announced on 13 March 2020 and updated on 21 November 2022), the Company now has 114,104 Ordinary Shares in issue and 78,324 C Shares in issue. With effect from today, the Company's Ordinary Shares will trade under the new ISIN number BMG1961Q3242 and the C Shares will trade under the new ISIN number BMG1961Q3168.

The applicable redemption ratios were 0.923631617 in relation to the Ordinary Shares and 0.905965573 in relation to the C Shares. On this basis, a holder of 1,000 Ordinary Shares will have had 923 Ordinary Shares redeemed, and receive $3,078.66 in cash. A holder of 1,000 C Shares will have had 905 C Shares redeemed, and receive $15,841.30 in cash. Approximately 91.73% of the issued share capital was redeemed.

In conformity with the FCA's Disclosure Guidance and Transparency Rules (DTR 5.6.1), the Company notifies that the Company's issued share capital now consists of 114,104 Ordinary Shares and 78,324 C Shares. Accordingly, the total number of voting rights in the Company is 192,428.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules (DTR 5.1.2).

It is expected that the proceeds of the redemption will be paid through CREST to holders of Ordinary Shares and C Shares in uncertificated form on 6 December 2022, and paid by cheque to holders of Ordinary Shares in certificated form on 8 December 2022.

Capitalised terms used but not defined in this announcement shall bear the meanings ascribed to them in the Circular to Shareholders dated 13 March 2020.

 Enquiries:

For further information:

 

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CASFKLLLLFLEFBB
Date   Source Headline
24th May 20064:36 pmRNSRule 8.3- Cambrdige Antibody
24th May 20064:24 pmRNSEPT Disclosure
24th May 20063:55 pmRNSRule 8.3- Cambridge Antibody
24th May 20063:35 pmRNSHolding(s) in Company
24th May 20063:20 pmRNSHolding(s) in Company
24th May 20061:40 pmRNSHolding(s) in Company
24th May 200612:16 pmRNSEPT Disclosure
24th May 200611:46 amRNSEPT Disclosure
24th May 200610:11 amRNSRule 8.3- Cambridge Antibody
24th May 20067:02 amRNSRule 8.1- Cambridge Antibody
23rd May 20066:07 pmRNSMarket Maker Holding
23rd May 20065:01 pmRNSEPT Disclosure
23rd May 20064:29 pmRNSRule 8.3- Cambridge Antibody
23rd May 20063:35 pmRNSRule 8.3- Cambridge Antibody
23rd May 20063:17 pmRNSRule 8.3- Cambridge Antibody
23rd May 200611:46 amRNSEPT Disclosure
23rd May 200611:46 amRNSRule 8.3- Cambridge Antibody
23rd May 200611:42 amRNSEPT Disclosure
23rd May 20067:01 amRNSAstraZeneca Offer for CAT
22nd May 20062:40 pmRNSRule 8.3- Cambridge Antibody
22nd May 20062:37 pmRNSRule 8.3- Cambridge Antibody
22nd May 200612:31 pmRNSEPT Disclosure
22nd May 200611:52 amRNSEPT Disclosure
22nd May 200611:41 amRNSEPT Disclosure
22nd May 20067:01 amRNSInterim Results
19th May 20065:41 pmRNSRule 8.3- Cambridge Antibody
19th May 20064:46 pmRNSEPT Disclosure
19th May 200612:49 pmRNSEPT Disclosure
19th May 200612:16 pmRNSEPT Disclosure
18th May 20065:08 pmRNSEPT Disclosure - Amendment
18th May 20065:05 pmRNSHolding(s) in Company
18th May 20064:28 pmRNSHolding(s) in Company
18th May 20064:27 pmRNSHolding(s) in Company
18th May 20064:25 pmRNSHolding(s) in Company
18th May 20064:00 pmRNSEPT Disclosure
18th May 20063:03 pmRNSRule 8.3- Cambridge Antibody
18th May 200611:44 amRNSEPT Disclosure
18th May 200611:21 amRNSNotice of Results
18th May 200611:08 amRNSEPT Disclosure
18th May 200610:54 amRNSHolding(s) in Company
18th May 20067:00 amRNSMarket Maker Holding
17th May 20063:46 pmRNSRule 8.3- Cambridge Antibody
17th May 20062:55 pmRNSEPT Disclosure - Amendment
17th May 200612:31 pmRNSEPT Disclosure
17th May 200612:28 pmRNSEPT Disclosure
17th May 200611:20 amRNSEPT Disclosure
17th May 200611:00 amRNSMerger Update
17th May 200610:31 amRNSRule 8.3- Cambridge Antibody
16th May 200612:41 pmRNSEPT Disclosure
16th May 200612:17 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.